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Abstract
Background: Senescence is a fundamental biological process implicated in various pathologies, including cancer.
Regarding carcinogenesis, senescence signifies, at least in its initial phases, an anti-tumor response that needs to be
circumvented for cancer to progress. Micro-RNAs, a subclass of regulatory, non-coding RNAs, participate in senescence
regulation. At the subcellular level micro-RNAs, similar to proteins, have been shown to traffic between organelles
influencing cellular behavior. The differential function of micro-RNAs relative to their subcellular localization and their
role in senescence biology raises concurrent in situ analysis of coding and non-coding gene products in senescent cells
as a necessity. However, technical challenges have rendered in situ co-detection unfeasible until now.
Methods: In the present report we describe a methodology that bypasses these technical limitations achieving for the
first time simultaneous detection of both a micro-RNA and a protein in the biological context of cellular senescence,
utilizing the new commercially available SenTraGorTM compound. The method was applied in a prototypical human
non-malignant epithelial model of oncogene-induced senescence that we generated for the purposes of the study.
For the characterization of this novel system, we applied a wide range of cellular and molecular techniques, as well as
high-throughput analysis of the transcriptome and micro-RNAs.
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Results: This experimental setting has three advantages that are presented and discussed: i) it covers a “gap” in the
molecular carcinogenesis field, as almost all corresponding in vitro models are fibroblast-based, even though the
majority of neoplasms have epithelial origin, ii) it recapitulates the precancerous and cancerous phases of epithelial
tumorigenesis within a short time frame under the light of natural selection and iii) it uses as an oncogenic signal, the
replication licensing factor CDC6, implicated in both DNA replication and transcription when over-expressed, a
characteristic that can be exploited to monitor RNA dynamics.
Conclusions: Consequently, we demonstrate that our model is optimal for studying the molecular basis of epithelial
carcinogenesis shedding light on the tumor-initiating events. The latter may reveal novel molecular targets with clinical
benefit. Besides, since this method can be incorporated in a wide range of low, medium or high-throughput image-
based approaches, we expect it to be broadly applicable.
Keywords: In situ hybridization, Micro-RNAs, Replication stress, Oncogene-induced senescence, CDC6, SenTraGorTM,
DNA damage response, R loops, rDNA, Cancer
Background
For almost half a century RNA was considered just the
coupler between DNA and protein production. On the
other hand, proteins represented the main workhorse of
the cell. This view has dramatically changed over the last
years, as regulatory RNAs emerged as a versatile compo-
nent of the molecular machinery interacting with both
DNA and proteins “shaping” gene expression and pro-
tein function, respectively [1, 2]. Mounting evidence
shows that this bidirectional interplay plays a vital role
in a variety of cellular responses, such as senescence; the
latter involved in the pathogenesis of various diseases,
including cancer.
Tumors are mixed tissues composed of cancer cells,
with a tremendous phenotypic plasticity (tumor hetero-
geneity), and normal recruited cells that form the
tumor-associated stroma [3, 4]. Under the microscope, a
spatial organization of malignant and surrounding
stromal cells is evident, implying a functional interplay
between the various cell populations. Indeed, tumor de-
velopment is mediated through a continuous “cross talk”
between intra-cellular molecular pathways and inter-
cellularly among cancer cells and the surrounding adja-
cent stroma [5]. The introduction of “-omics” increased
our perception of the underlying processes occurring
during carcinogenesis at a scale that has never been feas-
ible before. However, the results of high-throughput ana-
lyses are in fact heterogeneous signals deriving from all
the different cellular elements that comprise tumors.
Thus, the molecular signature of distinct, relatively small
tumor cell populations can be dramatically reduced or
even lost, eliminating the ability to comprehend their
contribution to cancer development. Hence, in situ
detection of biomolecules rises as a crucial necessity to
interrogate the mechanistic aspects of carcinogenesis.
In situ hybridization (ISH) and immune-localization
assays are valuable tools for detecting spatial features of
the transcriptional and translational machineries. ISH is
among the most frequent techniques employed for the
study of gene coding and non-coding RNAs (ncRNAs),
including micro-RNAs (miRs). miRs have been demon-
strated to play pivotal roles in multiple cell-fate deci-
sions [6–12]. They are short, ~22 nucleotides in length,
highly conserved and, although abundant, escaped notice
until 1993, when they were first reported by Lee,
Freinbaum and Ambros [13]. Biogenesis of miRs begins
with the generation of long primary transcripts, called pri-
mary miRs (pri-miRs), by RNA polymerase II (RNA pol
II) (Additional file 1: Figure S1). Subsequently, pri-miRs
are processed by Drosha, a class 2 RNase III, forming the
precursor miRs (pre-miRs) that are exported in the cyto-
plasm, by exportin-5. In the cytoplasm Dicer, a class 3
RNase III, produces the mature single strand that is
loaded on the RISC (RNA-induced silencing complex) ef-
fector complex [14, 15]. Pairing between miR and its tar-
get mRNA facilitated by Argonaute, a core component of
RISC, promotes post-transcriptional down-regulation by
cleavage and degradation (Additional file 1: Figure S1).
Besides their cytoplasmic localization and role, a number
of miRs have been discovered to function in the nucleus
[16]. The picture becomes even more fascinating, as miRs
have been detected in the mitochondria affecting their dy-
namics, further underscoring the importance of monitor-
ing miRs spatial distribution [17, 18] (Additional file 1:
Figure S1 and Additional file 2: Table S1).
Of particular interest is the role of miRs in cellular
senescence [19–22] (Additional file 3: Table S2). The lat-
ter is a fundamental biological process involved in tissue
homeostasis during normal development, and implicated
in a broad spectrum of pathologies, including cancer
[23–26]. In mammalian cells two types of cellular
senescence have been recognized; namely, replicative
senescence (RS) that occurs after certain number of cell
divisions due to telomere attrition and stress-induced
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premature senescence (SIPS) [27]. SIPS is telomere-
independent and represents an acute response to a wide
range of stressful stimuli long before telomere erosion
appears [27]. A decade ago, we and others demonstrated
that oncogenes trigger SIPS and that this response consti-
tutes a potent anti-tumor barrier [28–34]. This type of sen-
escence is referred to as “oncogene-induced senescence”
(OIS) [35] and according to the oncogene-induced DNA
damage model for cancer development, OIS must be
bypassed for tumor progression [36].
Even though senescence affects a variety of cell types,
the in vitro cellular models recurrently used to study the
phenomenon of OIS are almost always fibroblast-based
(Additional file 4: Table S3). As most common malig-
nancies are of epithelial origin, the lack of non-
malignant epithelial-derived models constitutes a major
“gap” in the field. The basic grounds for the rareness of
non-malignant epithelial-based cellular systems are: i)
the difficulty in maintaining the specialized epithelial
features during cultivation, rendering de-differentiation a
frequent outcome [37], and ii) the unsuccessful
immortalization with ectopic expression of human tel-
omerase reverse transcriptase (hTERT) in epithelial cells
in contrast to fibroblasts [38, 39].
Additionally, given the significance of miRs in senescence
biology and their diverse intracellular localization
(Additional file 1: Figure S1 and Additional file 2: Table S1)
we were surprised to notice that there are no in situ studies
of miRs in senescent cells (Additional file 3: Table S2). All
the reports suffer from the limitation of analyzing miRs by
qRT-PCR (quantitative reverse-transcription polymerase
chain reaction) or micro-arrays of RNA isolated from cell
cultures or tissues, independently scanned for senescence
markers; thus lacking cellular specificity in cases of
heterogeneity (Additional file 3: Table S2). The main rea-
son behind the absence of in situ miR studies relies on re-
straints of the currently applied method for detecting
senescence. The assay universally used, senescence-
associated β-galactosidase (SA-β-Gal) assay, is based on
the activity of β-galactosidase at suboptimal pH (pH 6.0).
Among the steps incorporated in this method are: i) in-
stant application on fresh cells/tissues to avoid loss of en-
zymatic activity; thus rendering prior RNA detection
unfeasible, and ii) a lengthy incubation of 12–16 h at 37 °C
in a complex ion buffer of pH 6.0 containing magnesium
ions (Mg+2) [40], conditions which negatively affect RNA
stability [41–45]. Although miRs are more stable than the
larger RNA species [46–48], they eventually undergo deg-
radation, as well [49, 50]. As recently shown, in urine sam-
ples stored for prolonged time at room temperature their
quantity decreases on average to 81% of their initial levels
at 24-h intervals [51]. Another potential source of RNA
degradation, during application of the aforementioned
method, may be the presence of RNases that are known to
be very stable enzymes and cannot be inactivated by the
fixative procedure applied by Dimri et al. [40, 52]. As a re-
sult, prolonged incubations at 37 °C may allow the decay
mechanisms to act in parallel exerting their activity.
We recently reported a universally applicable hybrid
histo−/immunohisto-chemical method that can bypass
all the aforementioned constraints of detection of senes-
cent cells [53]. This is a non-enzymatic assay based on
the property of a novel reagent, termed GL13, to detect
lipofuscin, a non-degradable metabolic by-product that
is considered a “hallmark” of senescence [54]. In the
present study, we have developed a method that enables
the simultaneous detection of gene coding (proteins)
and non-coding (miRs) products in GL13-reactive senes-
cent cells in situ. We have applied this methodology in an
epithelial cell model that over-expresses the replication li-
censing factor CDC6 (Cell division cycle 6) in an inducible
manner. We show that this cell system recapitulates the
whole spectrum of epithelial carcinogenesis from the non-
malignant stage to oncogene-mediated activation of the
anti-tumor barrier of senescence, followed by escape and
the production of aggressive clones with features of epi-
thelial to mesenchymal transition (EMT).
Results
The underlying principle for generating a CDC6-based
non-malignant human epithelial model to study
oncogene-induced senescence
According to a carcinogenesis model we have proposed,
activated oncogenes disrupt normal DNA replication
provoking replication stress that in turn triggers the
DNA damage response (DDR) pathway, promoting gen-
omic instability and cancer development [36]. An early
feature of this process is that specific loci of the genome,
called common fragile sites (CFS) are targeted resulting
in breaks, gaps and rearrangements [55, 56]. The car-
cinogenic process we describe is not an undemanding
procedure as incipient cancer cells need to evade the
anti-tumor barriers of apoptosis and senescence to
evolve into full-blown malignant cells [26, 36]. Thus,
roughly the model can be divided into two phases: the
first is typified by the activation of anti-tumor barriers,
and the second is characterized by escape from the
tumor-suppressor “blockade” driving cancer progression.
The type of anti-tumor response elicited, apoptosis or sen-
escence, is determined largely by the cellular context,
however almost all studies, as already mentioned, examine
the response to oncogene activation in mesenchymal-
based cellular settings (Additional file 4: Table S3).
Regarding the “escape from the tumor-suppressor
barriers”, the cancer biology field relies mainly on genetic
manipulation of potential anti-tumor network players and
monitoring of barrier circumvention. Although this ex-
perimental approach is useful in drawing conclusions
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about the role of a particular factor, it lacks the element of
“natural evolution”.
The requirement of a non-malignant model to
perform an epithelial cancer evolution experiment
(chronic expression of the oncogene without genetic
intervention upon its activation) led us to utilize human
bronchial epithelial cells (HBECs) as a platform to
generate an oncogene doxycycline-inducible (Tet-ON)
cellular system. Immortalization with combined ex-
pression of hTERT and ectopic mutant cyclin-dependent
kinase 4 (CDK4) was successful in order to bypass
p16INK4A-induced premature growth arrest (Additional file 5:
Figure S2), maintaining the epithelial phenotype of the cells
[57–59]. Further genetic manipulations to develop the
inducible system also did not affect the epithelial charac-
teristics of this model (Fig. 1a). We employed the replica-
tion licensing factor CDC6 as an inducible oncogene for
the following reasons: i) it is a key component of the repli-
cation licensing machinery, found to be frequently deregu-
lated in cancer from its earliest stages [60–62], and ii)
when over-produced it displays a multi-functional facet by
compromising the replication process (re-replication: a
form of replication stress) triggering genomic instability
[33, 60, 63, 64], and acquiring properties of a transcrip-
tional regulator affecting: a) negatively the expression of
the nodal tumor-suppressors loci, INK4/ARF (encoding
p16INK4A, ARF and p15INK4B) and CDH1 (encoding
E-cadherin) [62, 63, 65] (Additional file 6: Figure S3),
Fig. 1 Epithelial cancer evolution experiment (ECEE) in a CDC6-expressing non malignant epithelial model. a-b Generation and validation of the
HBEC CDC6 Tet-ON cellular system. a Schematic representation of the lentiviral vectors (PLVX-Tet3G-BSD and PLVX-TRE3G-CDC6-BleoR) utilized for
CDC6 transduction in HBECs (see details in “Methods” section). HBECs preserve their epithelial phenotype upon ectopic expression of hTERT and
mutant CDK4 for immortalization. Inverted-phase contrast microscopy showed preservation of the epithelial morphology in HBECs upon transduction
with lentiviruses, followed by treatment with antibiotics in order to isolate clones with inducible CDC6 over-expression. Scale bar: 10 μm. b Efficiency
of CDC6 induction was confirmed both at protein (western blot) and mRNA (qRT-PCR) levels at the indicated time points. c Plot showing inverse
relationship between proliferation rate, as measured by BrdU incorporation overnight, and senescent phenotype, as assessed by GL13 staining [53],
during the time course of CDC6 induction. d Morphological and kinetic features observed by inverted-phase contrast microscopy (Scale bar: 20 μm),
GL13 staining (Scale bar: 20 μm) and wound healing assay (Scale bar: 80 μm) at specific time points of ECEE representing normal, precancerous and
cancerous stages of tumorigenesis. Non-induced cells (“OFF”) are near normal, 6-day induced cells recapitulate precancerous lesions, where senescent
cells are evident (dark orange cells in cartoon [s]), and cells that have escaped from senescence (“ESCAPED”) share the invasive characteristics of cancer
cells (dark green cells in cartoon [i]). A continuous counter-interaction between the oncogenic acting force and the anti-tumor reacting force
(senescence) takes places at the precancerous stage, leading eventually to the prevalence of the tumor promoting effect, bypass of senescence and
emergence of cancer cells [36]
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and b) positively that of rDNA (ribosomal DNA), most
probably impinging on RNA dynamics [66].
Epithelial cancer evolution experiment (ECEE)
Subsequent to validating the efficacy of CDC6 induction
in the newly formed HBEC CDC6 Tet-ON system
(Fig. 1b), we constitutively expressed it at levels relevant
to those of tumor samples and monitored the cellular
behavior over time. Stimulation of CDC6 resulted in a pro-
gressive decrease of cell proliferation, as depicted by re-
duced BrdU (bromodeoxyuridine) incorporation (Fig. 1c),
that ceased after 6 days of induction. As proliferation di-
minished, the cells after a 3-day induction gradually ac-
quired a senescent phenotype, as depicted by GL13
staining [53], that peaked at day 6 (Fig. 1c-d and Add-
itional file 7: Figure S4). This finding is in line with a
previous study where we showed that forced expression of
CDC6 in human fibroblasts, induced senescence in a
DDR-dependent manner [33]. Compared to fibroblasts,
we were surprised by the robustness of this reaction in
HBECs. This is quite intriguing given that senescence
seems to be the predominant stress response program in
fibroblasts, whereas apoptosis is believed to be the preva-
lent route in epithelial cells [67]. However, a recent report
showing CDC6-mediated inhibition of apoptosome for-
mation through its binding onto cytochrome c-activated
Apaf-1 [68], probably explains why senescence emerges as
the only tumor suppressor mechanism in our system.
From a morphological point of view, microscopical ana-
lysis revealed enlarged and flattened cellular shapes, occa-
sionaly multinucleated (Fig. 1d and Additional file 7:
Figure S4), without the appearance of senescence associ-
ated heterochromatin foci (SAHF). Notably, this feature is
observed during irreversible senescence in cells with an
intact p16INK4A/Rb pathway, justifying its absence in our
system [69]. On the other hand, the senescent cells pre-
sented extensive vacuolation, as well as the formation of
extracellular vesicles indicative of increased secretoty ac-
tivity, which may be related to the senescence associated
secretory phenotype (SASP), the so called “dark side” of
the senescent program accountable for its protumorigenic
properties [26] (Fig. 2a). After a protracted stalled growth
phase (around a month), when all cells were senescent
and uniformaly expressed CDC6 (Figs. 1d and 2b-c and
Fig. 2 Phenotypic characterization of HBEC CDC6 Tet-ON system during ECEE. a Ultrastructural analysis of 6 days induced cells revealed flattened
cellular morphology, with enlarged nucleus (N), enhanced protein-synthesis, as visualized by double nucleoli (n) and extensive Golgi apparatus
(G), and formation of extracellular vesicles (v). Arrows depict extracellular vesicles. Scale bars 2 μm and 500 nm. b IF analysis of the proliferative
marker (Cyclin A) and CDC6 showed double positive cells only after escape from senescence. Scale bar: 15 μm. c IF for an epithelial marker
(E-cadherin) or a mesenchymal marker (Vimentin) along with CDC6 indicated EMT in the “escaped” cells. IF for CDC6 showed ubiquitous and
uniform expression in the induced cells (“ON” and “ESCAPED”). Scale bar: 20 μm
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Additional file 7: Figure S4), a fraction of proliferating cells
emerged with distinct morphological features compared
to those of the “OFF” state. These cells, from now on
termed “escaped”, showed traces of lipofuscin during the
first cell divisions, proving that they came from senescent
cells, while they were negative for GL13 after several pas-
sages and serial dilutions of the non-degradable metabolic
by-product (Fig. 1d and Additional file 7: Figure S4).
Moreover, they were double positive for CDC6 and Cyclin
A, a well characterized cell proliferation marker (Fig. 2b).
Unexpectedly, they attained a spindle morphology resem-
bling that of mesenchymal cells (Fig. 1d and Additional file 7:
Figure S4), insinuating an EMT, an embryonic program
implicated in cancer invasion and progression [70, 71]. In
accordance, E-cadherin, a fundamental adhesion molecule
of epithelial tissues, was lost in the “escaped” cells,
identifying a cardinal feature of the EMT program,
whereas vimentin, a mesenchymal marker, increased
(Fig. 2c) [71]. From a kinetic angle, carrying out a migra-
tion assay (wound healing assay) we observed that the
“escaped” cells migrated significantly faster than the non-
induced ones, whereas the senescent cells were completely
still (Fig. 1d). To sum up, we developed an in vitro
oncogene-regulated non-malignant human epithelial
model that could compellingly recapitulate the precancer-
ous and cancerous phases of the model we proposed
(Fig. 1d) [36].
Mechanistic insights into the senescent and escape
phases of the ECEE
To gain a mechanistic view underlying the phenotypic
phases we described (Figs. 1-2 and Additional file 7:
Figure S4) we followed a dual approach: i) based on our
prior knowledge, we hypothesized and examined, whether
senescence was DRR-induced [33, 36, 60, 72–74] and ii)
we performed high-throughput analyses of transcriptome
and miRs. We performed transcriptome analysis at two
time points, one at day 3 (initiation of the senescent phase)
and a second during the “escaped” phase (evolution of the
protumorigenic phase) to unravel potential cancer initiat-
ing and driver events, respectively, while we added another
time point at day 6 (full senescent phenotype) in order to
reveal a potential miR signature of the senescent cells.
In line with our previous reports [33, 60, 75], CDC6
induction resulted in re-replication (cells with DNA con-
tent > 4n) (Fig. 3a), a form of replication stress, that
leads to replication fork stalling, collapse, DNA damage
and DDR activation. DNA damage was documented by
alkaline comet assay (Fig. 3b), and DDR stimulation by
53BP1 foci formation and induction of the p53 pathway
(Fig. 3c). The emergence of the “escaped” cells was dis-
tinguished, apart from the EMT features, by the attenu-
ation of the DNA damage and the DDR pathway,
implying that a repair process took place. A cytogenetic
analysis of the “escaped” cells, relative to the non-induced
Fig. 3 DNA damage and DDR activation upon CDC6 induction are reduced in the “escaped” cells. a Cell cycle analysis upon CDC6 induction and
plot of re-replicating cells (DNA content > 4n). b Comet assay showed DNA breaks in cells induced for the indicated time points. DNA damage
was significantly reduced in the “escaped” cells. Plot depicts tail comet (moment) calculations. Red lines depict moment tails. Scale bar: 35 μm.
c DDR activation in CDC6-induced cells as demonstrated by double IF for 53BP1 and CDC6 (Scale bar: 20 μm) along with western blotting for
p53 and p21WAF1/Cip1. DDR is reduced in the “escaped” cells. Actin serves as a loading control.
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Fig. 4 (See legend on next page.)
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(OFF) ones, revealed the presence of an altered karyotype,
implying that this repair process was error-prone. The "-
escaped" cells harbored novel clonal (numerical and struc-
tural) chromosomal alterations and an increased rate of
random structural chromosome rearrangements, indica-
tive of genomic instability (Fig. 4a-b and Additional file 8:
Figure S5) [76, 77]. Of note, we have observed a similar
molecular response in cells that “escaped” from protracted
p21WAF/Cip1-mediated senescence [64]. Remarkably, the
majority of the novel breakpoints identified in the
“escaped” HBECs coincided with aphidicolin-induced CFS
(Fig. 4c) [78], a finding that is in line with the proposed
oncogene-induced DNA damge model for cancer develop-
ment [36]. Interestingly, the karyotype of the “escaped”
cells was also characterized by gains of 1q and 5p and de-
letions of 8p23.1, which are frequently found in common
solid cancers and various hematologic malignancies, and
are associated with poor prognosis [79–82].
Even though replication stress via re-replication can
explain CDC6-mediated genomic instability, a recent re-
port showing that CDC6 could regulate rDNA transcrip-
tion initiation [66] led us to presume that an additional
source of genomic instability could be R loop formation.
R loops are three-stranded nucleic acid structures that
encompass nascent RNA hybridized with DNA template,
leaving single-stranded the non-template DNA (ssDNA)
[83] (Additional file 9: Figure S6). Their formation and/or
stabilization, which follows transcription, depends on
various factors such as, high G density, negative supercoil-
ing, DNA nicks and G-quartets in the displaced ssDNA
[84, 85], and if persistent they set genome integrity at
“risk” [83]. They are also frequently produced at CFS, re-
gions of the genome prone to replication stress, located in
long human genes (≥ 800 kb); thus increasing the possibil-
ity of replication-transcription collision and genomic in-
stability [56]. The fact that R loops are reported in vivo at
origins of replication [86–90] and rDNA loci [91, 92] in-
creases the probability of their formation by deregulated
expression of the replication licensing factor, CDC6.
To examine the above scenario we first measured total
transcription levels by quantifying 5′-ethynyl uridine
(5’-EU) incorporation at specific time points, pre- and
post-CDC6 induction. We observed a gradual increase
of 5’-EU integration that peaked in the “escaped” cells
(Fig. 5a). Re-replication and RNA production could
well form a permissive genome landscape for the gen-
eration of R loops. Indeed, applying a specific anti-
body that detects DNA:RNA hybrids (S9.6) revealed a
raise in R loop formation within the nucleoli in the
initial phases of CDC6 expression that ceased during
senescence, possibly due to recession of DNA replica-
tion, but reappeared in the “escaped” cells (Fig. 5b).
The specificity of the reaction was verified by treat-
ing the cells with RNase A or RNase H, enzymes
specific in removing DNA:RNA hybrids [93, 94]
(Fig. 5b). If R loops were related to DNA damage in
our setting, then a repositioning of damaged rDNA
on the nucleolar surface should occur facilitating re-
cruitment of repair factors. This type of peripheral
re-localization of the repair process is characteristic of
heterochromatin enriched structures, such as the nucleoli
[95, 96]. In agreement with the latter, induction of CDC6
in HBECs resulted in the re-localization of UBF (upstream
binding factor) signifying rDNA [97], from nucleolar inter-
ior to the periphery, where it is associated with 53BP1 foci,
forming nucleolar caps (Fig. 5c) [96].
It has been suggested that R loops may demonstrate dis-
similar structural features depending on their role within
the cell. They could be characterized as “Janus-face” mod-
ules with beneficial or adverse functions; the nature of
which has not been linked with particular structural traits,
yet [98]. Within this context, vimentin expression (Fig. 2c),
a cardinal trait of EMT, in the “escaped” cells could be R
loop-dependent, as previously reported [99]. Transcrip-
tome analysis of the “escaped” cells revealed elevated
expression of factors that prevent or remove R loops,
whereas most of them were reduced during the initial
phases of CDC6 induction (Fig. 5d, Additional file 10:
(See figure on previous page.)
Fig. 4 Cytogenetic analysis revealed an altered karyotype in the “escaped” cells, displaying novel clonal numerical and structural chromosome
aberrations coinciding with common fragile sites (CFS). a Multi-Color FISH spectral karyotyping (M-FISH/SKY) of the non-induced and the “escaped”
HBECs combined with inverted DAPI banding, as described in [143], revealed a near diploid numerical constitution of 48 chromosomes. Yellow arrows
indicate unique clonal rearrangements for each population whereas the blue arrows depict the common structural anomaly der(16)t(5;16). b Partial
karyotypes in Inverted DAPI Banding demonstrate the breakpoints of clonal structural chromosome rearrangements in the two populations, OFF
(upper panel) and “escaped” (lower panel). nl: normal copy. Several clonal structural rearrangements characteristic of the control cells (OFF), were lost
in the cytogenetically examined “escaped” cells; these included the products of the translocation t(7;18), der(7)t(7;18)(q11.2;q22.2)(found in two copies)
and der(18)t(7;18)(q11.2;q22.2). Lost in the “escaped” cells were also the der(19)t(17;19)(p13.3;q23.1) and the extra copy of chromosome 20 bearing a
duplication of the long arm. Despite the clonal chromosome losses, the “escaped” cells displayed at least 6 novel clonal structural chromosome
anomalies and their cytogenetic constitution was shaped by non-disjunctions of chromosomes 1, 5, 7, 12 16, 18 and 19. The karyotype of the "escaped"
cells was characterized by the clonal gain of genomic material from 1q and most of chromosome 12, introduced by the emergence of the novel
unbalanced translocation involving chromosomes 1 and 12, der(12)t(1;12)(p11;q24.1), as well as deletions of 8p23.1. In addition to these novel
anomalies, the “escaped” cells presented an unbalanced translocation involving chromosomes 6 and 9, an extra copy of a rearranged derivative of
chromosome 9, a translocation between 16 and 20 and two copies of isochromosome 5p. c Breakpoints of all the novel structural chromosome
rearrangements identified in the “escaped” HBECs coincide with common aphidicolin induced fragile sites [78]
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Figure S7 and Additional file 11: Table S4). The differen-
tial expression of these R loop-affecting factors in the
“escaped” cells compared to early stage CDC6-induced
ones may be viewed as an adaptation to the high demand
for protein-synthesis of the “escaped”-protumorigenic
cells; thus reducing the risk for replication-transcription
collisions at the rDNA loci possibly favoring the beneficial
effects of the R loops.
In an attempt to reveal functional modules related to
cancer initiation and progression we adjusted the data
from the transcriptome and the cytogenetic analyses
(Figs. 4 and 6) to the “hallmarks” of cancer [4, 73, 100].
Fig. 5 CDC6 induction resulted in R loop formation. a CDC6 induction increased total transcription levels, as measured by 5’-EU incorporation.
Scale bar: 35 μm. b IF for S9.6, antibody specific for DNA:RNA hybrids, indicated increased possibility of R loop formation upon CDC6 expression.
Concurrent IF detection of nucleolin, revealed nucleolus subcellular localization of the R loops. DNA:RNA hybrids disappeared after treatment with
RNase A or RNase H showing the specificity of the reaction. Scale bar: 15 μm. c Double IF for 53BP1 and UBF showed re-localization of UBF from
the nucleolar interior to the periphery associated with the perinucleolar distribution of 53BP1 foci (indicated by white arrows) reflecting DNA damage
repair in heterochromatin-related structures [96]. Scale bar: 10 μm. d Heatmap of factors affecting R loops (Additional file 11: Table S4) [98]
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As depicted in Fig. 6 the results further strengthened the
value of HBEC CDC6 Tet-ON cellular system to study
“escape from senescence” and carcinogenesis, as the
“escaped” cells share most of the cancerous characteristics,
adopting a stress phenotype [101]. Of note, transcripto-
mics showed different transcriptome landscapes affecting
major biological processes in the senescent versus the "-
escaped" cells (Fig. 6d). Moreover, gene-set enrichment
analysis demonstrated that the cell cycle-associated path-
way and DNA replication were essentially stopped in the
induced cells and significantly up-regulated once the cells
escaped from senescence (Additional file 12: Figure S8). In
the analysis, we did not include “limitless replicative
potential”, as ectopic expression of hTERT could lead to
artificially positive results. Notably, the only “hallmarks”
that could not be scored as statistically significant
were those of “evading immune surveillance” and
“sustained angiogenesis”, probably due to the lack of
surrounding stroma.
GlobalmiR expression analysis (miRseq) (Additional file 13:
Table S5) yielded similar to RNAseq results, showing
significantly different profiles between the senescent and "es-
caped" populations (Fig. 7). Two miRs were of particular
interest: miR34c and miR29a. The first one showed
significant up-regulation in the CDC6 over-expressing
cells at day 3, followed by a further rise at day 6,
whereas in the "escaped" cells, its levels fell below
those observed in the non-induced cells, verified by
qRT-PCR analysis (Additional file 14: Figure S9). Accord-
ing to reports, miR34c along with a panel of additional miRs
up-regulated at day 6, are related to senescence (Add-
itional file 15: Table S6). On the other hand, miR29a
showed an inverse pattern. Of note, miR29a has been
shown to play a role in EMT [102]. Interestingly, emerging
data support that down-regulation of miR34 genes, in-
cluding miR34c, are also implicated in EMT through a
negative feedback loop with SNAIL, which comes in line
with our findings [103]. Over-represented pathways, gene
a
b c
d
Fig. 6 Transcriptome analysis of HBEC CDC6 Tet-ON cellular system. a Timeline of ECEE (epithelial cancer evolution experiment) showing time
points where main biochemical and phenotypical events occur. High-throughput RNA sequencing analysis that was performed on 3-day induced
(initiation of senescence phase) and in the “escaped” cells, compared to non-induced ones, revealed extensive alterations in the transciptome
landscape. b Heatmap, showing hierarchical clustering, and (c) Venn diagram of the deregulated genes indicated that most of them were
exclusive features of either of the two time points and not common ones nominating that they share different traits. d Adjustment of the
transcriptome analysis to the “hallmarks” of cancer, utilizing Gene Ontology (GO) terms as shown in table, revealed that the “escaped” cells share
the characteristic features of cancer cells. DDR/R refers to DNA damage response and repair pathways
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ontologies and target genes are summarized in -
Additional file 16: Table S7.
In situ co-detection of gene coding (protein) and
non-coding (miR) products during OIS
As mentioned, the role of miRs in senescence is well
established [19, 20, 22]. However, the technical limita-
tions of the SA-β-Gal method (see Background section),
has rendered miR in situ detection in senescent cells un-
feasible so far. The advantages of the GL13 reagent and
the described features of the HBEC CDC6 Tet-ON sys-
tem (induction of senescence, escape from senescence
and activation of the DDR-p53 pathway) prompted us to
explore this model for monitoring, in situ, the spatio-
temporal expression pattern of a gene coding (protein)
and non-coding (miR) product functionally linked with
the processes of DDR and senescence. Prompted by the
miRseq analysis we selected miR34c as a miR target.
MiR34a-c are amongst the best-characterized direct
transcriptional downstream targets of p53, placing them as
bona fide components of the p53 network [104]. In
addition, miR-34s, including miR34c, were reported to trig-
ger senescence in various human lung settings [104, 105].
On the other hand, 53BP1 is an ideal protein target since
it is a well-established upstream mediator of the DDR
pathway, which is recruited to sites of double strand
breaks (DSBs) forming discrete foci [55, 106–108]. For in
situ co-detection we followed a three-step immuno-
fluorescence process: i) Fluorescence in situ hybridization
(FISH) for miR34c, followed by ii) GL13 staining to spot
senescent cells, and finally iii) detection of 53BP1 foci.
Successful GL13 staining and 53BP1 foci formation
(steps ii and iii) were independently confirmed
during the validation of the HBEC CDC6 Tet-ON
Fig. 7 MiR analysis of HBEC CDC6 Tet-ON cellular system. a Principal component analysis of miR profiles showing that after escaping from the
senescence programme, the cells reverted to the pre-induction stage, but considerable alterations of their miR expression persisted. b Hierarchical
clustering of miRs that showed significant differences between the non-induced (OFF), induced (3d On and 6d On) and escaped from senescence
(Escaped) cells
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system, as shown in Figs. 1d and 3c and Additional
file 7: Figure S4b, respectively.
Due to the challenging nature of the 3-step co-
detection procedure, detailed technical aspects, control
and trouble-shooting processes are described meticu-
lously in the Additional file 17 and illustrated in
Additional file 18: Figure S10. Only the principles of the
in situ assay are presented and discussed in the current
section. Step 1; miR34c detection: Before proceeding
with ISH of miR34c, its expression following CDC6 in-
duction was confirmed by qRT-PCR (Additional file 14:
Figure S9). For ISH we employed the Locked Nucleic
Acid (LNA) technology [109–111]. LNAs are nucleic
acid analogues “locked” by a methylene bridge that con-
strains them in the ideal conformation for Watson-Crick
binding allowing superior hybridization properties [112]
(Additional file 19: Figure S11). To increase detection
sensitivity we used double-digoxigenin (DIG) labeled (at
both 5′ and 3′ ends) probes visualized with the
Tyramide Signal Amplification (TSA) Plus Fluorescein
System emitting at 517 nm [113–115]. Although the
water-soluble 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide (EDC) increases signal strength, we omitted it since
it interferes with protein detection [116]. As negative and
positive controls of the method we employed Double-DIG
labeled Scramble-miR and U6 small nuclear RNA (snRNA)
probes, respectively (Additional file 20: Figure S12). Step 2;
Detection of senescent cells: To detect miR34c positive
senescent cells we employed the GL13 reagent [53] that
overcomes the restrictions of the SA-β-Gal assay (see
Background section) allowing examination of the sensitive
to decay miR molecules to precede senescence detection.
Step 3; Detection of 53BP1 foci: Finally, we proceeded
with 53BP1 foci detection using conventional immuno-
fluorescent (IF) analysis. Each secondary antibody emitted
at different wave-lengths to avoid overlapping during
visualization (see Methods section, Figs. 8 and 9).
As depicted in Figs. 8 and 9 following a two (steps 1
and 2) and a three step (steps 1, 2 and 3) process we
successfully co-detected miR34c in senescent cells that
clearly showed evidence of DDR activation (53BP1 foci).
For each step a parallel experiment took place, omitting
the primary reagent (miR34c probe, GL13 and anti-
53BP1 antibody), to exclude false positive staining from
the secondary antibodies. Notably, miR34c was not
detected in the “escaped” cells (Fig. 9), which is in agree-
ment with the miRseq and qRT-PCR analysis
(Additional file 14: Figure S9), probably because of de-
clined p53 levels in these cells (Fig. 3c).
Discussion
A major challenge in understanding the pathogenesis of
cancer is the availability of models that functionally re-
capitulate observations from human clinical settings. A
successful model addresses the following questions: How
relevant is it to human cancer? What type of human
cancer does it mimic? Is the recapitulated event an
initiating or a promoting one? How can it help
Fig. 8 In situ detection of miR34c in senescent cells. Detection of miR34c in senescent cells employing the HBEC CDC6 Tet-ON system. Double
staining was performed in two consecutive states: in the OFF state where proliferation of HBECs is evident (“OFF”) and 6 days after constitutive
induction of CDC6 when cells are senescent (“6d ON”). Step 1: Fluorescence FISH of miR34c employing a double-DIG-labeled LNA probe, visualized as
green emission in the cytoplasm, using TSA plus Fluorescein (emitting at 518 nm). Step 2: GL13 staining, visualized at far red spectra as granules in the
cytoplasm employing Alexa Fluor goat-anti-mouse (647 nm) (emitting at 668 nm). Scale bar: 50 μm
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uncover or predict mechanism(s) that could be thera-
peutically targeted?
While in vivo mice models are the first choice, their
development is costly and time consuming. Moreover,
their relevance to human carcinogenesis has been ques-
tioned despite the large body of knowledge gained till
now [117]. In mice the quantity of genetic events
required for cellular transformation is lower compared
to humans [100, 118], whereas qualitative alterations dif-
fer, as well. As an example, in humans activated onco-
genes are encountered mainly by the DDR pathway,
while in mice activation of the p19ARF tumor-
suppressor predominates [58, 59, 119–121]. Additionally,
telomeres in humans are shorter than in mice, possibly
Fig. 9 Monitoring concurrently in situ miRs and proteins expression during OIS. Co-detection of miR34c and 53BP1 in senescent cells, employing
the HBEC CDC6 Tet-ON system and our proposed protocol (see Additional file 17 and Additional file 18: Figure S10). Multiple staining was performed
in three consecutive states: in the OFF state where proliferation of HBECs is evident (“OFF”), 6 days after constitutive induction of CDC6 when cells are
senescent (“6d ON”) and in the “escape from senescence” state termed “ESCAPED”. Step 1: miR34c FISH employing a double-DIG-labeled LNA probe,
visualized as green emission in the cytoplasm, using TSA plus Fluorescein (emission at 518 nm). Step 2: GL13 staining, visualized at far red spectra as
granules in the cytoplasm employing Alexa Fluor goat-anti-mouse (647 nm) (emission at 668 nm). Step 3: 53BP1 IF, visualized as red foci in the nucleus,
employing Alexa Fluor goat-anti-mouse (568 nm) (emission at 618 nm). The specificity of each individual probe/antibody was tested by omitting
sequentially the following reagents: miR34c probe, GL13 and anti-53BP1 antibodies at 6d ON cells. U6 snRNA and Scramble FISH, serving as positive
and negative controls respectively, are presented in the Additional file 20: Figure S12. Scale bar: 20 μm
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as an anti-tumor protective mechanism to eliminate cells
that have acquired dangerous mutations during the rela-
tive long human lifespan [122].
Human cell lines represent established alternatives as
they are more relevant to human disease, although there
are certain limitations, such as the absence of complex
intercellular and cell-matrix interactions that exist in in
vivo models [100]. Still, they facilitate the direct interro-
gation of cancer associated genetic events, like oncogene
activation, and their impact on cellular outcomes, such
as evasion from the anti-tumor barriers of apoptosis and
senescence [36].
In this study, we developed and present an original
human non-malignant epithelial (bronchial) oncogene-
inducible cellular system that recapitulates the precancerous
and cancerous phases of epithelial carcinogenesis precisely,
within a relatively short time frame (Figs. 1 and 6a).
Non-malignant epithelial platforms are generally rare as
most researchers prefer fibroblast- or cancer cell line-
based settings because they are manipulated much easier.
However, the cellular context determines to a great extent
the carcinogenetic process. Given that the majority of can-
cers are of epithelial origin, non-malignant epithelial
systems are essential to study the initiating events of epi-
thelial carcinogenesis. Prompted by the fact that our
model showed a potent senescent response, following
oncogene activation, we took advantage of GL13, a novel
senescence biomarker we synthesized, and monitored
concurrently in situ miR and protein expression, for the
first time, during OIS. The latter was not feasible until
now due to inherited flaws of SA-β-Gal, the currently
available method [40], whereas GL13 enables detection of
senescent cells in any given biological material [53].
As a triggering oncogenic stimulus we favored the rep-
lication licensing factor CDC6 mainly because it is fre-
quently over-expressed in various epithelial cancers from
their earliest stages of development [60, 61]. Moreover,
we previously showed that its deranged expression is not
a mere reflection of increased proliferation but a
potential “driving force”, as suggested by the oncogene-
induced replication stress model for cancer develop-
ment, we proposed few years ago [33, 36, 62]. Lying in
the heart of the replication machinery we anticipated
that CDC6 induction in the HBEC setting would mimic
from an evolutionary perspective the precancerous and
cancerous stages of epithelial cancer development.
Indeed, CDC6 over-expression provoked a rapid sen-
escent response that was maintained for a prolonged
period (precancerous phase) (Fig. 1 and Additional file 7:
Figure S4). In parallel, at the molecular level an intense
DDR response was noticed, which is in line with previ-
ous reports demonstrating a functional link between
DDR and acquirement of senescence [33, 34, 64, 72, 74].
The most interesting finding appeared at day 30 post-
induction when cellular clones with phenotypical and
molecular traits of EMT emerged (“escaped” cells -
cancerous phase) (Figs. 1d and 2c and Additional file 7:
Figure S4). EMT is an embryonic program that confers
to cancer invasion and progression when reactivated at
the “wrong time” [70, 71]. The DDR was alleviated in
the “escaped” cells implying that an extensive repair
process occurred. Judging from the novel clonal and ran-
dom chromosomal alterations observed in the “escaped”
cells (Fig. 4 and Additional file 8: Figure S5), an error-
prone repair procedure probably took place, the exact
nature of which remains to be elucidated. A similar
process has been recently described during chronic
p21WAF1/Cip1 expression in a p53-independent environ-
ment [64]. In addition to the EMT features, the
“escaped” cells possessed most of the hallmarks of
cancer, as depicted from the transcriptome analysis of
the “escaped” versus the non-induced cells (Fig. 6d),
clearly pinpointing the value of our cellular system to
study induction and escape from senescence.
Apparently and in agreement with the oncogene-
induced replication stress model for cancer development,
CDC6-driven genomic instability exerted a selective pres-
sure that led to the evolution of the “escaped” cells. The
fact that this process was raised during the senescent phase
puts forward a scenario according to which senescence
should not be viewed as a “static” state, but as a “dynamic”
one, when the genome landscape is continuously reformed
and shaped. Although re-replication is “incriminated” as
the means by which CDC6 causes DNA damage, the
current study unraveled that R loops could represent and
additional source of CDC6 mediated genomic instability
[83]. R loop formation occurred within the nucleoli, het-
erochromatin nuclear substructures comprised by the
rDNA region. The rDNA locus is a highly repetitive region
of the genome consisting of tandem repeats encoding the
rRNA subunits and is enriched with origins of replication.
The latter along with the fact that CDC6 was shown to ac-
tivate the transcription of rDNA [66] renders its loci prone
to R loop formation, replication-transcription collision and
DNA damage. In support to this notion, we observed in
CDC6-induced HBECs redistribution of UBF to the per-
iphery of the nucleoli localized adjacent to 53BP1 foci,
forming the so-called nucleolar caps (Fig. 5c) [96]. Having
in mind that UBF is the main transcription factor of rDNA
[123] and repair of heterochromatin DNA takes place at its
periphery [95, 124], we can deduce that R-loop formation
in our setting most probably led to DNA damage; thus
contributing to CDC6-driven genomic instability.
Conclusively, we believe that the experimental system we
present can inspire further mechanistic studies and address
questions such as which origins of replication deregulated
CDC6 activates. Are they intergenic or intrangenic? In the
latter case what is the risk of replication-transcription
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collision? What type of error-prone repair pathway(s) en-
sues during CDC6 induced senescence? Are the transcrip-
tional properties of deranged CDC6 restricted only to the
INK4/ARF, CDH1 (E-cadherin) and rDNA loci or does
CDC6 mediate a global transcriptional program? If yes, does
it involve displacement of the chromosomal insulator CTCF
as it does for the INK4/ARF and CDH1 loci? Moreover, with
regard to the miRseq analysis, which of the detected miRs
are directly involved in inducing senescence and which are
implicated in the escape phenomenon? All the above ques-
tions and their answers gain particular worth within the
context of the non-malignant epithelial environment of our
system as they most probably signify cancer initiating
events.
Conclusions
The desire to simultaneously detect multiple intracellu-
lar macromolecules has its roots back to late 60’s [125].
Despite progress in the development of in situ detection
assays during the last decades, multiple in situ staining
still remains a challenge. This is pertinent to the field of
senescence because of the additional practical limitations
exerted by the application of the SA-β-Gal assay.
Prompted by this widespread need, we have developed
and described herein a methodology that bypasses these
restrictions. We have provided proof-of-principle that
this methodology maintains optimal preservation of the
biological setting and tremendous flexibility, enabling
gold standard ISH techniques to be combined with
antigen detection and senescence marker recognition.
To validate the new method, we have developed a cell
system based on human bronchial epithelial cells that re-
capitulates the whole spectrum of epithelial carcinogen-
esis following the inducible over-expression of the
replication licensing factor CDC6. The vast majority of
in vitro models used to study processes related to malig-
nant transformation are fibroblast-based, which contrast
the fact that most malignancies are of epithelial origin.
Thus, the HBEC CDC6 Tet-ON epithelial system
emerges as a valuable prototypical tool that possesses
the following advantages: i) It enables phenotypic and
molecular monitoring of OIS and escape from senes-
cence, recapitulating the precancerous and cancerous
phases of human epithelial carcinogenesis. In the future
it could be applied in co-cultures with stromal cells;
hence investigating the interplay between the various
phases of OIS and the surrounding cellular environment.
ii) The properties of CDC6 acting concurrently as a rep-
lication and transcription factor, when deregulated, will
facilitate the in-depth study of genome dynamics, such
as re-replication, replication-transcription collision,
DNA repair in conjunction with transcriptional deregu-
lation, and chromatin remodeling. Along these lines we
have observed temporal formation of R loops that cease
during senescence and reappear upon escape. iii) Apply-
ing the senescence detecting reagent GL13, which lacks
the limitations of the SA-β-Gal assay, provides the
unique opportunity to monitor co-currently in situ both
proteins and regulatory RNAs, such as miRs. Moreover,
the utilization of the GL13 compound for detection of
lipofuscin is applicable not only to track senescence, but
also to monitor escape from it. The latter is due to the
fact that lipofuscin is non-degradable, accumulating pro-
gressively and is diluted only through cell divisions. As a
result, traces of lipofuscin in the cells escaping from sen-
escence can be detected rendering it a unique lineage
tracing marker [126]. We expect that this cell model,
coupled with the multifaceted applications that the new
macromolecule detection methodology offers, will en-
able a more direct examination of the spatiotemporal
expression of miRs and gene-coding products relevant
to senescence and malignant transformation.
Methods
Cell culture, plasmids and HBEC CDC6 Tet-ON system
generation
The Lenti-X™ Tet-On® 3G Inducible Expression System
(Clontech Laboratories) was employed to establish a
CDC6 inducible-expression cellular model in immortal-
ized HBECs (hTERT/CDK4) [57], which were a kind gift
of Dr. T. Liloglou.
PLVX-TRE3G-CDC6 was generated by digesting
pTRE2Hyg-CDC6 [63] with BamHI and EcoRV (blunt end)
and subcloning MYC-tag-hCDC6-cDNA into PLVX-
TRE3G linearized with BamHI and SmaI (blunt ended).
Immortalized HBECs are resistant to G418 due to the
neomycin-resistant gene introduced with the CDK4 expres-
sion vector (pSRα-MSU) and to puromycin due to the
corresponding-resistant gene introduced with p-babe-
hygro-hTERT. Given that PLVX-TET3G and PLVX3G-
TRE-CDC6 carry also neomycin-resistant and puromycin-
resistant genes, accordingly, it was necessary to replace
the resistance cassettes of lentiviral vectors with
blasticidin-resistant (BSD) and zeocin-resistant (BleoR)
genes. Particularly, IRES-BSD from pBIB was transferred
into pBluescript SK with EcoRI–ClaI and then obtained
with KpnI and BamHI to replace IRES-Neo-WPRE from
PLVX-TET3G using partial digestion. BleoR was derived
from Lenti X1 zeo-pTERshATM with XbaI-filled ends and
KpnI to replace puromycin-restistant cassette of
PLVX3G-TRE-CDC6 obtained with MluI-filled ends and
KpnI. For a schematic presentation of vectors see Fig. 1a.
Production of lentiviruses and transduction were per-
formed according to supplier’s guidelines utilizing Lenti-X™
Concetrator (Clontech Laboratories). After two-week se-
lection with 3 μg/mL blasticidin and 12.5 μg/mL zeocin,
cell clones with doxycyclin-dependent (1 μg/mL, Sigma)
induction of CDC6-MYC-tagged, as assessed by
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immunoblot and real-time qRT-PCR analyses (Fig. 1a),
were isolated and used for the described experiments.
Upon CDC6 induction, doxycyclin was replenished every
second day.
Immortalized HBECs and HBEC CDC6 Tet-ON cells
were maintained in Keratinocyte Serum-Free Medium
(#17005–075, Invitrogen) supplemented with 50 μg/ml
Bovine Pituitary Extract and 5 ng/ml hEGF (#17005–075,
Invitrogen) at 37 °C and 5% CO2 [57].
Microphotographs were obtained with an inverted
microscope (Axiovert S100; Carl Zeiss) equipped with
CP-Achromat objectives and a charge-coupled device
IRIS colour video camera (SSC-C370P; Sony), using
Image Pro Plus v3.0 (Media Cybernetics) software.
Total protein extraction and western blot analysis
Total protein extracts were obtained by homogenization
in 50 mM Tris/HCl pH 8.0, 150 mM NaCl, 0,1% SDS,
0,5% sodium deoxycholate, 1% NP-40 adjusted with pro-
tease and phosphatase inhibitors. The homogenate was
centrifuged at 13,400 rpm at 4 °C for 10 min. The super-
natant was collected and protein content quantified using
Protein assay dye concentrate (BIO-RAD). Thirty μg of
protein from total extracts, were adjusted with Laemmli
Buffer (Sigma) and loaded on acrylamide/bis-acrylamide
gels. Gel electrophoresis, transfer to PVDF membrane
(Millipore) and signal development with chemilumines-
cence substrate ECL for HRP (PerkinElmer) were per-
formed as previously described [60]. Primary antibodies
were used at the following dilutions: CDC6 (Santa Cruz
#9964) 1:1000, p-RB (Santa Cruz #7986-R) 1:500, RB
(Santa Cruz #50) 1:1000, p53 (Santa Cruz #47698) 1:1000,
p21WAF1/Cip1 (Santa Cruz #6246, 1:400), Actin (Cell
Signaling #4967, 1:1000). Anti-mouse (Cell Signaling
#7076) and anti-rabbit (Cell Signaling #7074) HRP-linked
secondary antibodies diluted at 1:1000 were used.
RNA isolation, cDNA preparation and qRT-PCR
RNA was extracted using Nucleospin RNA (Macherey-
Nagel #740955) according to the manufacturer’s instruc-
tions. 1 μg RNA was used for cDNA preparation with Pri-
mescript™ RT Reagent Kit (Takara #RR037A). Real-time
qRT-PCR analysis was performed utilizing SYBR Select
Master Mix (Life technologies #4472908) on a DNA-
Engine-Opticon (MJ-Research) thermal cycler. Primer
sequences are as follows, CDC6 forward: 5’-CAGTT
CAATTCTGTGCCCGC-3′ and reverse: 5’-GCTCCTTCT
TGGCTCAAGGT-3′, β2-microglobulin (reference gene)
primers were forward: 5’-TCGCGCTACTCTCTCTTTCT-3′
and reverse: 5’-TTTCCATTCTCTGCTGGATGAC-3′.
Results, averaged from three independent experiments,
are presented as n-fold changes for the various time points
after CDC6 induction versus the values of the non-
induced sample, using the 2-ΔΔCT method.
For miR detection, RNA was extracted with the
NucleoSpin miR, kit/50preps (Cat no: 740971.50;
Macherey-Nagel), following the manufacturer’s instruc-
tions. For reverse transcription the TaqMan® MicroRNA
RT Kit, 200 RXNS (Cat no: 4366596, ThermoFischer Sci-
entific) along with TaqMan® Universal Master Mix II
with UNG (Cat no: 4440042, ThermoFischer Scientific)
and the two TaqMan® MicroRNA Assays Inv sM10
(Cat no: 4427975, ThermoFisher Scientific) were
employed. The assays ID for each of the corresponding
primers and probes are the following: a) hsa-miR-34c
(target assay): 000428 and b) U6snRNA (control assay):
001973. Expression of miR-34c was calculated relative to
U6snRNA levels according to the comparative method of
2-ΔΔCT. Relative quantification of miR expression was
calculated from three independent biological replicates.
ChIP assay
ChIP assay was performed in HBEC CDC6 Tet-ON cells
grown in 100 mm plates and induced for 2 days. Cells
were cross-linked with 1% formaldehyde in 50 mM
Hepes-KOH pH 7.5, 100 mM NaCl, 1 mM EDTA
pH 8.0, 0.5 mM EGTA pH 8.0 for 15 min at RT on a
rocking platform. Cross-linking was stopped by the
addition of glycine to a final concentration of 125 mM
for 5 min at RT on a rocking platform. Cross-linked cells
were washed twice with ice cold PBS, scraped and cen-
trifuged at 3000 rpm for 5 min. Approximately 6 × 106
cells were resuspended in 2 ml of lysis buffer (50 mM
Hepes pH 7.9, 140 mM NaCl, 1 mM EDTA, 10% gly-
cerol, 0.5% NP-40, 0.25% Triton-X100) and incubated
for 10 min on ice in the presence of protease and phos-
phatase inhibitors. Cells were then washed twice in
10 mM Tris-HCl pH 8.1, 200 mM NaCl, 1 mM EDTA
pH 8.0, 0.5 mM EGTA pH 8.0, two more times in shear-
ing buffer (0,1% SDS, 10 mM Tris-HCl pH 8.1, 1 mM
EDTA pH 8.0) and resuspended in 1 ml of shearing buf-
fer in the presence of protease and phosphatase inhibi-
tors. Cells were sonicated with a Covaris S2 sonicator for
15 min. Triton-X100 and NaCl was added to a final
concentration of 1% and 150 mM, respectively. The
debris was pelleted by 10-min centrifugation at
13000 rpm at 4 °C, and the soluble chromatin material
was precleared with salmon sperm DNA/50% protein A
agarose slurry. Further steps were performed as de-
scribed before [63].
BrdU proliferation assay
For BrdU incorporation, cells grown on coverslips were
pulse-labeled with 10 μM BrdU (Roche) overnight at
37 °C. Cells with incorporated BrdU were treated and
visualized by indirect IF analysis as described in the
corresponding methodology subsection.
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Senescence/GL13 staining
GL13 staining was performed as described before [53].
GL13 compound is commercially available as
SenTraGor™ from Arriani Pharmaceuticals (Cat no:
AR8850040).
SA-β-gal assay
SA-β-Gal activity was detected according to Debacq-
Chainiaux et al. [127].
Wound healing assay
Cells were seeded on 100 mm tissue-culture plastic
dishes at 70% confluence and, the next day, a scratch
wound was performed using a sterile 200 μl pipette tip.
Phase-contrast images were taken at the starting (0 h)
time point and at 8 h and 24 h time intervals using an
inverted microscope (Axiovert S100; Carl Zeiss).
Electron microscopy analysis
Cells were fixed in a freshly-prepared solution contain-
ing 3% formaldehyde (prepared from paraformaldehyde)
and 0.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4,
for 30 min at room temperature (RT). Cells were then har-
vested using a scraper, collected into a tube and centri-
fuged at 800 g for 5 min at RT. The supernatant was
aspirated, while cells were resuspended in 4% gelatin
warmed aquatic solution followed by a spin down at 800 g
for 5 min at RT and cooled on ice. Under a stereoscope the
solidified cell pellet with gelatin was extracted, cut into
small fragments (1–2 mm3) and transferred into 0.1 M
phosphate buffer, pH 7.4 at 4 °C. The cell-gelatin fragments
were then dehydrated in graded series of ethyl alcohol,
followed by propylene oxide (PO) treatment, infiltrated
gradually in a mixture of Epon/Araldite resins diluted in
PO and finally embedded in fresh epoxy resin mixture.
Ultrathin epoxy sections (70-90 nm thickness) were cut on
a Leica Ultracut R ultramicrotome, equipped with a
Diatome diamond knife, and mounted onto 200-mesh cop-
per grids. Ultrathin sections were observed with a Philips
420 transmission electron microscope and micrographs
were taken with an Olympus Megaview G2 CCD camera.
Indirect IF analysis
For indirect IF analysis cells were grown on coverslips and
fixed with 100% ice-cold methanol or 4% formaldehyde
(prepared from paraformaldehyde) for 10 min and store at
4 °C until staining was performed. Following, cells were
permeabilized with 0,3% Triton X-100 in PBS for 5 min at
RT. A 10% fetal bovine serum and 3% bovine serum albu-
min in PBS solution was used as a blocking buffer for 1 h
at RT. Primary antibodies were diluted in blocking buffer
and incubated overnight at 4 °C. Secondary antibodies
were goat anti-rabbit or goat anti-mouse, Alexa Fluor® 488
or Alexa Fluor® 568 (Invitrogen) diluted 1:500 in blocking
buffer. Counterstaining was performed with 100 ng/ml
DAPI (Sigma-Aldrich). Primary antibodies used were:
CDC6 (Santa Cruz #9964, 1:100 or #8341, 1:50), Cyclin A
(Santa Cruz #239, 1:150), E-cadherin (Cell Signaling
#3195 1:200), Vimentin (Dako M0720, 1:50) 53BP1
(abcam #21083, 1:250), S9.6 (Kerafast ENH001, 1:200),
nucleolin (Cell Signaling #14574, 1:1000) and UBF (Santa
Cruz #13125, 1:100). For S9.6 IF, treatment with RNase A
(0.25 μg/μl) or RNase H (50 units/slide) at 37 °C for
30 min and 3 h, respectively, was performed if necessary.
Image acquisition from multiple random fields was
automatically obtained on a ScanR screening station
(Olympus, Germany) and analyzed with ScanR (Olympus,
Germany) software, or a Zeiss Axiolab fluorescence
microscope equipped with a Zeiss Axiocam MRm camera
and Achroplan objectives, while image acquisition was
performed with AxioVision software 4.7.1.
Flow cytometric analysis (FACS)
Cell cycle analysis was assessed on a FACS Calibur
(Becton-Dickinson) as previously described [63].
Comet assay
Comet assay was performed with minor modifications of a
standard previously described protocol [63]. In brief, after
trypsinization and wash in PBS, 200,000 viable cells were
resuspended in 225 μl of TBE (Tris–Boric acid–EDTA) buf-
fer, mixed with 1275 μl of low melting agarose embedded
in plugs. Plugs were subsequently incubated in 10 ml lysis
solution (100 mM Tris-HCl, 100 mM EDTA, and 2.5 M
NaCl, pH 10, with the addition of 1.25% Triton X-100 and
10% DMSO, before use) overnight on ice and in the dark.
After completion of lysis, plugs were washed twice in TBE
for 30 min on ice in the dark. Finally, plugs were washed
and subsequently incubated in ice-cold alkaline denatur-
ation buffer (300 mM NaOH and 1 mM EDTA, pH 13) for
45 min on ice in the dark. For electrophoresis, plugs were
mounted onto 1% agarose-coated slides that were placed
into a 30-cm horizontal constant-field gel electrophoresis
chamber in ice-cold alkaline denaturation buffer for 30 min
at 0.7 V/cm and at 4 °C. After electrophoresis, slides were
washed 3 times in TBE, dehydrated in ice-cold ethanol
(100%) for 15 min and then allowed to dry in the dark. 24 h
later, slides were rehydrated in 5 ml of deionized water for
10 min, and 40 μl of diluted SYBR gold (Invitrogen,
Molecular Probes) was applied on each plug. Cells were ob-
served under a fluorescence microscope (Axiolab) equipped
with a monochrome UV camera (XC-EU50 CE; Sony).
Analysis was conducted using the CometScore software
(TriTek Corp.).
5’-EU incorporation based nascent RNA assay
In situ detection of nascent RNA was performed with
the Click-iT Alexa Fluor 488 Imaging Kit (Invitrogen,
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Molecular Probes). Briefly, cells were incubated for
30 min in the presence of 0.5 mM 5-EU. Samples were
fixed in 4% formaldehyde for 15 min and permeabilized
in 0.5% Triton X-100 for 20 min at RT. Samples were
then processed according to the manufacturer’s re-
commendation. Cells were analyzed using LSM780 or
LSM710 (Carl Zeiss Microscopy) confocal microscopes
and 5-EU nuclear intensity was quantified with the NIS-
elements software (Nikon).
Molecular Cytogenetics
Molecular cytogenetics analysis was conducted as previ-
ously published [63]. Specifically, a 63× magnification
lens on a fluorescent Axio-Imager Z1, Zeiss microscope
equipped with a MetaSystems charge-coupled device
camera and the MetaSystems Isis software were used.
RNA-sequencing (RNAseq) and miR-sequencing (miRseq)
preparation and analysis
The library preparation for RNAseq and miRseq was
carried out in the Greek Genome Center (GGC) of
Biomedical Research Foundation of Academy of Athens
(BRFAA). RNA was collected from biological duplicates
of HBEC CDC6 Tet-ON non-induced (OFF), 3d ON
and “escaped” cells. RNAseq libraries were prepared with
the TruSeq RNA kit using 1 μg of total RNA. The librar-
ies were constructed according to Illumina’s protocols
and then were mixed in equal amounts. Paired-end
38 bp reads for 2 “OFF”, 2 “ON” and 2 “ESCAPED” sta-
tus samples were generated with NextSeq500 in the
GGC. RNAseq raw sequencing data were aligned to
human genome version GCCh37/hg19 with the use of
tophat (version 2.0.9) [128] and the use of «–b2-very-
sensitive» parameter. Data filtering and file format con-
version was performed with Samtools (version 0.1.19)
[129]. Aligned reads were assigned into exons using HT-
seq count (version 0.6.1p1) algorithm [130] with the
following command «htseq-count –s no –m intersec-
tion -nonempty». Finally differentially expressed genes
were identified with the use of DESeq R package [131]
and genes with at least 10 reads, fold change cut off 1.5
and p-value ≤0.05 were considered to be differentially
expressed (DEGs) (Additional file 11: Table S4).
For miRseq the procedure was carried out differently.
After automatic filtering, adapter trimming, error re-
moving and quality control using AfterQC [132], good
quality reads were mapped directly to miRbase (release
21) database of all mature miR sequences using Novo-
craft’s NovoAlign tool. This allowed us to create raw
count tables accounting for every present miR. Raw
counts were then normalized using standard transcripts
per million (tpm) normalization. Length of miRs was ac-
quired from miRbase v21. Four groups were compared:
non-induced cells (OFF), induced ones (ON at 3 and
6 days) and "escaped" from senescence (ESC). MiRs
present in at least 10 transcripts per million in at least
three samples from any of the groups were selected for
comparisons, yielding the total number of 269 unique
miRs ready for analysis. The four groups were compared
with one-way ANOVA. MiRs with Bonferroni-adjusted
p < 0.05 were entered into a hierarchical clustering and
principal component analyses (Additional file 13:
Table S5). Post-hoc comparisons between the groups
were performed using a Tukey’s test.
Bioinformatic and functional analyses
DAVID knowledgebase [133] was used for Gene
Ontology analysis. Only pathways and biological pro-
cesses with p-value ≤0.05 (Fisher’s exact test) were
considered to be significantly enriched. RNAseq data
have been deposited in the Short Read Archive (SRA)
under the accession codes PRJNA388146. Gene set
enrichment analysis (GSEA) [134] was performed using
the canonical pathways (Cp2) subset of the molecular
signatures database [http://software.broadinstitute.org/
gsea/msigdb/].
For miRs, the over-representation analysis was per-
formed using miRNA enrichment analysis miEAA [135].
Over-represented pathways and gene ontologies were
searched using the miRWalk and the search for target
genes utilized the miRTarBase as reference. To account
for multiple comparison problems we lowered the
threshold for statistical significance to 0.001 as it was
impossible to fully adjust for multiple hypothesis testing
and the number of between group analyses. Additionally,
the threshold of at least 3 miRs present in the analyzed
sets was applied. MiRseq data have been deposited in
GEO with accession number GSE106588.
Additional files
Additional file 1: Figure S1. Biogenesis pathway and subcellular
localization of miRs. miRs are mainly transcribed by RNA pol II, while a cluster
of miRs flanked by Alu repeats on chromosome 19 (C19MC) are transcribed
by RNA pol III [136], into pri-miRs (>1kb long) with a hairpin structure [137].
Pri-miRs are recognized by Drosha, a class 2 RNAase III, and an RNA binding
protein (RBP) called DGCR8/Pasha. Drosha cleaves the 5’ and 3’ arm of the
hairpin releasing pre-miRs (~70bp long). The latter are exported through the
nuclear pores into the cytoplasm by Exportin 5 in association with Ran-GTP. In
the cytoplasm processing of pre-miRs is mediated by Dicer, a class 3 RNase III,
which along with various RBPs, including TRBP, stabilize Dicer. Dicer-TRBP
complex liberates small RNA duplexes that are loaded onto Argonaute protein
members (Ago1-4) forming effector complexes called pre-RISCs. Pre-RISCs
remove the passenger miRs strand generating the mature form of RISCs
encompassing single strand miRs (~22 nucleotides long each). The functional
strand of miRs loaded on Ago1-4 guides RISCs to silence target mRNAs in the
cytoplasm (C) through translational repression, mRNA cleavage and
deadenylation [138]. Additionally, miRs may translocate into: a) the nucleus (N)
[16], regulating the biogenesis of coding and non-coding RNAs (active RISC
complexes are present in the nucleus (nRISC) having a distinct composition
from cytoplasmic RISC (cRISC) [139]) and b) the mitochondria (M) bound to
Ago2 at pre-RISC or mature RISC complex (mRISC) [17], regulating the
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translation of the mRNAs produced by mitochondrial genome which, in turn,
modulate mitochondrial homeostasis [140]. Evidence also supports the
presence of mitochondrial miRs encoded by mitochondrial genome [18]. A
substantial fraction of miRs may also exist in the cytoplasm in an Ago-free
form [141]. Notably, apart from DGCR8 and TRBP, different RBPs recognize
distinct miR precursors regulating miR biogenesis [142]. (PDF 1025 kb)
Additional file 2: Table S1. Subcellular localization of miRs.
(XLSX 12 kb)
Additional file 3: Table S2. Studies on miR expression in senescent
cells. (XLSX 20 kb)
Additional file 4: Table S3. Genes triggering oncogene-induced
senescence. (XLSX 12 kb)
Additional file 5: Figure S2. RB phosphorylation in HBEC CDC6 Tet-ON
system. Immunoblot analysis of total and phosphorylated RB levels. CDK4
over-expression in HBEC results in continuous phorsphorylation of RB
protein, while induction of CDC6 increased p-RB due to transcriptional
down-regulation of p16 [63]. Actin serves as loading control. (PDF 21 kb)
Additional file 6: Figure S3. CDC6 binding onto the promoters of
CDH1 and INK4/ARF loci of HBEC CDC6 Tet-ON system leading to
transcriptional down-regulation. a) Chromatin immunoprecipitation (ChIP)
assay showed that MYC-tagged CDC6 is bound on both the regulatory
domain (RD) of INK4/ARF locus and the Epal element of CDH1, when
induced. b) RD of INK4 locus is enriched in DNA extracted from both
anti-CDC6 (endogenous and exogenous) and anti-MYC-tag (exogenous)
IPs in HBEC CDC6 over-expressing cells normalized to input and INK4b
intron (RNA Pol II-IP serves as a negative control confirming transcriptional
down-regulation). c) ChIP samples run on a SDS-PAGE gel revealed that
CDC6 is accessible and immunoprecipitated by both CDC6 and MYC-tag
antibodies with the protocol followed. (PDF 146 kb)
Additional file 7: Figure S4. Morphological features of HBEC CDC6
Tet-ON. a) Inverted-phase contrast photographs (Scale bar: 25 μm) and
bi) GL13 staining showed the dominance of senescent, flattened and
multinucleated cells upon 6-day CDC6-induction; features that were
substituted by a spindle morphology in the “escaped” cells. Traces of
GL13 staining in the early "escaped" cells (indicated by arrows) prove
their origin from senescent cells. bii) Sa-β-Gal activity correlates with
GL13 staining. (Scale bar: 15 μm). (PDF 689 kb)
Additional file 8: Figure S5. Comparative Inverted DAPI Banding
karyotyping of 20 metaphase spreads from the OFF (on the left) and the
“escaped” (on the right) cells. Arrows indicate random chromosome
rearrangements (chromosomal instability). The rates of random structural
chromosome rearrangements were found 3.5-times more pronounced in
the "escaped" cells. (PDF 554 kb)
Additional file 9: Figure S6. Schematic presentation of an R loop. R
loops are three-stranded nucleic acid structure. Factors (upper left corner)
that promote R loops are indicated as well as the differential cellular
effects (bottom) stemming from their formation. (PDF 557 kb)
Additional file 10: Figure S7. Bedgraphs of indicative genes showing
the specificity of RNAseq analysis. RNAseq data from two biological
replicates is depicted. (PDF 47 kb)
Additional file 11: Table S4. A Upregulated genes in induced (ON)
HBEC CDC6 Tet-ON cells. b Down regulated genes in induced (ON) HBEC
CDC6 Tet-ON cells. c Upregulated genes in ESCAPED (ESC) HBEC CDC6
Tet-ON cells. d: Down regulated genes in ESCAPED (ESC) HBEC CDC6
Tet-ON cells. (XLSX 630 kb)
Additional file 12: Figure S8. Enrichment plots a-b) of the “Cell cycle
mitotic” and c-d) of the “DNA replication” gene-sets. Cells entering
senescence (3-day induced) showed a significant (Bonferroni-adjusted
p value <0.001) down-regulation of cell-cycle and DNA replication
pathways in comparison to control ones. These changes were reversed
with a significant up-regulation (Bonferroni-adjusted p value <0.001) of
both sets when the cells escaped from senescence. (PDF 528 kb)
Additional file 13: Table S5. A MiR expression differences between
induced (3d ON) and non-induced (OFF) HBEC CDC6 Tet-ON cells.
FWER - Bonferroni-adjusted p value. b MiR expression differences
between induced (6d ON) and non-induced (OFF) HBEC CDC6 Tet-ON cells.
FWER - Bonferroni-adjusted p value. c MiR expression differences
between "escaped" (ESC) and non-induced (OFF) HBEC CDC6 Tet-ON cells.
FWER - Bonferroni-adjusted p value. d MiR expression differences
between 3-day induced (3d ON) and 6-day induced (6d ON) HBEC CDC6
Tet-ON cells. FWER - Bonferroni-adjusted p value. e MiR expression
differences between "escaped" (ESC) and induced (3d ON) HBEC CDC6
Tet-ON cells. FWER - Bonferroni-adjusted p value. f MiR expression differences
between "escaped" (ESC) and induced (6d ON) HBEC CDC6 Tet-ON cells.
FWER - Bonferroni-adjusted p value. (XLSX 134 kb)
Additional file 14: Figure S9. miR-34c expression analysis in OFF, ON
and “ESCAPED” HBEC CDC6 Tet-ON cells utilizing: a) qRT-PCR and
b) miRseq analysis, tpm (transcripts per million). (PDF 25 kb)
Additional file 15: Table S6. Potential miR signature of senescence
according to miRseq analysis of HBEC CDC6 Tet-ON system and existing
literature. (XLSX 9 kb)
Additional file 16: Table S7. MiR enrichment analysis showing
pathways, Gene Ontology terms and Target genes significantly linked to
differentially-expressed miRs between respective groups.Fields marked
out in bold represent pathways present in at least two pairwise comparisons.
(XLSX 20 kb)
Additional file 17: Supplementary methods. (see also Additional file 18:
Figure S10). (DOC 91 kb)
Additional file 18: Figure S10. Flowchart of the protocol employed to
co-detect in situ gene coding (protein) and non-coding (miR) products
during OIS in the HBECs CDC6 Tet-ON system. See also Additional file 17.
(PDF 116 kb)
Additional file 19: Figure S11. Hybridization probes incorporating
nucleotide analogs based on the LNA technology. (PDF 144 kb)
Additional file 20: Figure S12. Detection of U6 snRNA and
scramble-miR miRNACURY control double-DIG labeled probes
employing TSA plus Fluorescein system. Scale bar: 30 μm.
(PDF 74 kb)
Abbreviations
5’-EU: 5′-ethynyl uridine; BrdU: Bromodeoxyuridine; CDC6: Cell division cycle
6; CDK4: Cyclin-dependent kinase 4; CFS: Common fragile sites;
ChIP: Chromatin immunoprecipitation,; DDR: DNA damage response;
DGCR8: DiGeorgi critical region 8; DIG: Double-digoxigenin; DSB: Double
strand break; ECEE: Epithelial cancer evolution experiment; EDC: 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide; EMT: Epithelial to mesenchymal
transition; FACS: Flow cytometric analysis; FISH: Fluorescence in situ
hybridization; GO: Gene ontology; HBEC: Human bronchial epithelial cells;
hTERT: Human telomerase reverse transcriptase; IF: Immunofluorescence;
ISH: in situ hybridization; LNA: Locked nucleic acid; M-FISH/SKY: Multicolour
fluorescence in situ hybridization/spectral karyotypicing; miR: Micro-RNA;
ncRNA: Non-coding RNA; OIS: Oncogene-induced senescence; Pasha: Partner
of Drosha; PO: Propylene oxide; pre-miR: Precursor micro-RNA; pri-miR: Primary
micro-RNA; qRT-PCR: Quantitative reverse-transcription polymerase chain reac-
tion; RBP: RNA binding protein; RD: Regulatory domain; rDNA: Ribosomal DNA;
RISC: RNA-induced silencing complex; RNA pol: RNA polymerase; RNAseq: RNA
sequencing; RS: Replicative senescence; RT: Room temperature;
SAHF: Senescence associated heterochromatin foci; SASP: Senescence associated
secretory phenotype; SA-β-Gal: Senescence-associated β-galactosidase;
SIPS: Stress-induced premature senescence; snRNA: Small nuclear RNA;
ssDNA: Single-stranded; TRBP: TAR RNA-binding protein; TSA: Tyramide signal
amplification; UBF: Upstream binding factor
Acknowledgements
We would like to thank Professor Niels Ødum for helpful discussions,
Dr. A. Kotsinas for his valuable support to this work, Dr. S. Havaki for help
with the electron microscopy analysis, Dr. G. Panagopoulos for the RNAseq
and miRseq analysis, as well as Dr. I. Kloukina and Prof. Capetanaki of the
Center of Basic Research at Biomedical Research Foundation of Academy of
Athens (BRFAA), for the use of Transmission Electron Microscope. We also
thank C. Kotsi and I. Svolaki for technical support.
Komseli et al. BMC Genomics  (2018) 19:37 Page 19 of 22
Funding
V.G.G and E.-S.K. received a National Scholarships Foundation-Siemens
Aristeia Fellowship. C.P.Z. was financially supported from the European
Union’s Horizon 2020 research and innovation programme under the Marie
Sklodowska-Curie grant agreement No. 722729. Financial support was also
provided by SARG-NKUA code 70/3/12128 and 70/3/8916. TK and NØ were
supported by research funding from the Danish Research Council, the
Danish Cancer Society and the Novo Nordic Foundation while TK was further
supported by a Sapera Aude Talent Grant (DFF-4092-00122) from the Danish
Council for Independent Research.
Availability of data and materials
RNAseq data have been deposited in the Short Read Archive (SRA) under
the accession codes PRJNA388146. MiRseq data have been deposited
in GEO with accession number GSE106588. The GEO submission is
published and available using https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE106588.
Authors’ contributions
E-SK developed the cellular system. ISP, SVR, EP, CPZ and TK participated in
cell culture and conducted in situ techniques (FISH, senescence staining,
double and triple detections). E-SK, IM, SG and IPT performed cell culture
manipulations, cell growth assays, SA-β-Gal assay, immunoblots, IF analysis,
RNA/miR isolation, qRT-PCR, comet assay, electron microscopy, FACS
analysis and ChIP. AP, KS, WF and CD performed RNAseq and miRseq along
with the analysis of the results. FMR, MC and SG performed the cytogenetic
analysis. D-EP and EON were responsible for the design, experimental
procedure and interpretation of the 5’-EU assay and provision of specialized
reagents. IM, CPZ and TK conducted literature search and Table preparation.
E-SK and ISP performed figure preparation. AGE and JB assisted in data
analysis. VGG designed the experiments, supervised the project and wrote
the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Molecular Carcinogenesis Group, Department of Histology and Embryology,
School of Medicine, National & Kapodistrian University of Athens, 75 Mikras
Asias St, GR-11527 Athens, Greece. 2Department of Immunology and
Microbiology, University of Copenhagen, Blegdamsvej 3c, DK-2200
Copenhagen, Denmark. 3Department of Biostatistics and Translational
Medicine, Medical University of Lodz, 15 Mazowiecka St. 92-215, Lodz,
Poland. 4Biomedical Research Foundation of the Academy of Athens, 4
Soranou Ephessiou St, GR-11527 Athens, Greece. 5Department of Cell Biology
and Biophysics, Faculty of Biology, National & Kapodistrian University of
Athens, GR-15784 Athens, Greece. 6CRUK/MRC Institute for Radiation
Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ,
UK. 7Department of Biology, School of Medicine, National & Kapodistrian
University of Athens, 75 Mikras Asias St, GR-11527 Athens, Greece. 8Institute
of Molecular Biology and Biotechnology, Foundation for Research &
Technology-Hellas, GR-70013 Heraklion, Crete, Greece. 9Department of
Radiation Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston,
MA 02215, USA. 10Harvard Medical School, 25 Shattuck St, Boston, MA 02115,
USA. 11Genome Integrity Unit, Danish Cancer Society Research Centre,
Strandboulevarden 49, DK-2100 Copenhagen, Denmark. 12Institute of
Molecular and Translational Medicine, Faculty of Medicine and Dentistry,
Palacky University, Hněvotínská, 1333/5, 779 00 Olomouc, Czech Republic.
13Department of Medical Biochemistry and Biophysics, Karolinska Institute,
Science for Life Laboratory, Division of Translational Medicine and Chemical
Biology, SE-171 77 Stockholm, Sweden. 14Faculty of Biology, Medicine and
Health, University of Manchester, Manchester Academic Health Science
Centre, Wilmslow Road, Manchester M20 4QL, UK.
Received: 12 July 2017 Accepted: 11 December 2017
References
1. Braunschweig U, et al. Dynamic integration of splicing within gene
regulatory pathways. Cell. 2013;152(6):1252–69.
2. Brosius J. The persistent contributions of RNA to eukaryotic gen(om)e
architecture and cellular function. Cold Spring Harb Perspect Biol. 2014;
6(12):a016089.
3. Jiao Y, Torquato S. Emergent behaviors from a cellular automaton model for
invasive tumor growth in heterogeneous microenvironments. PLoS Comput
Biol. 2011;7(12):e1002314.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
5. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that
interface with the entire organism. Dev Cell. 2010;18(6):884–901.
6. Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation:
shared themes amid diversity. Nat Rev Genet. 2008;9(11):831–42.
7. Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet.
2013;14(8):535–48.
8. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease.
Cell. 2012;148(6):1172–87.
9. Eguchi T, Kuboki T. Cellular reprogramming using defined factors and
MicroRNAs. Stem Cells Int. 2016;2016:7530942.
10. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.
11. Gruber AJ, Zavolan M. Modulation of epigenetic regulators and cell fate
decisions by miRNAs. Epigenomics. 2013;5(6):671–83.
12. Erhard F, et al. Widespread context dependency of microRNA-mediated
regulation. Genome Res. 2014;24(6):906–19.
13. Lee RC, Feinbaum RL, Ambros V. The C. Elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14. Cell.
1993;75(5):843–54.
14. Olena AF, Patton JG. Genomic organization of microRNAs. J Cell Physiol.
2010;222(3):540–5.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281–97.
16. Rasko JE, Wong JJ. Nuclear microRNAs in normal hemopoiesis and cancer.
J Hematol Oncol. 2017;10(1):8.
17. Srinivasan H, Das S. Mitochondrial miRNA (MitomiR): a new player in
cardiovascular health. Can J Physiol Pharmacol. 2015;93(10):855–61.
18. Barrey E, et al. Pre-microRNA and mature microRNA in human
mitochondria. PLoS One. 2011;6(5):e20220.
19. Williams J, et al. Are microRNAs true sensors of ageing and cellular
senescence? Ageing Res Rev. 2017;35:350–63.
20. Abdelmohsen K, Gorospe M. Noncoding RNA control of cellular senescence.
Wiley Interdiscip Rev RNA. 2015;6(6):615–29.
21. Bischof O, Martinez-Zamudio RI. MicroRNAs and lncRNAs in senescence: a
re-view. IUBMB Life. 2015;67(4):255–67.
22. Olivieri F, et al. DNA damage response (DDR) and senescence: shuttled
inflamma-miRNAs on the stage of inflamm-aging. Oncotarget.
2015;6(34):35509–21.
23. Campisi J, Robert L. Cell senescence: role in aging and age-related diseases.
Interdiscip Top Gerontol. 2014;39:45–61.
24. Munoz-Espin D, Serrano M. Cellular senescence: from physiology to
pathology. Nat Rev Mol Cell Biol. 2014;15(7):482–96.
25. Giaimo S, d'Adda F. Di Fagagna, is cellular senescence an example of
antagonistic pleiotropy? Aging Cell. 2012;11(3):378–83.
26. Gorgoulis VG, Halazonetis TD. Oncogene-induced senescence: the bright
and dark side of the response. Curr Opin Cell Biol. 2010;22(6):816–27.
27. Sikora E, et al. Impact of cellular senescence signature on ageing research.
Ageing Res Rev. 2011;10(1):146–52.
28. Braig M, et al. Oncogene-induced senescence as an initial barrier in
lymphoma development. Nature. 2005;436(7051):660–5.
29. Chen Z, et al. Crucial role of p53-dependent cellular senescence in
suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725–30.
30. Collado M, et al. Tumour biology: senescence in premalignant tumours.
Nature. 2005;436(7051):642.
31. Lazzerini Denchi E, et al. Deregulated E2F activity induces hyperplasia and
senescence-like features in the mouse pituitary gland. Mol Cell Biol. 2005;
25(7):2660–72.
32. Michaloglou C, et al. BRAFE600-associated senescence-like cell cycle arrest
of human naevi. Nature. 2005;436(7051):720–4.
Komseli et al. BMC Genomics  (2018) 19:37 Page 20 of 22
33. Bartkova J, et al. Oncogene-induced senescence is part of the tumorigenesis
barrier imposed by DNA damage checkpoints. Nature. 2006;444(7119):633–7.
34. Di Micco R, et al. Oncogene-induced senescence is a DNA damage response
triggered by DNA hyper-replication. Nature. 2006;444(7119):638–42.
35. Serrano M, et al. Oncogenic ras provokes premature cell senescence associated
with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593–602.
36. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage
model for cancer development. Science. 2008;319(5868):1352–5.
37. Geraghty RJ, et al. Guidelines for the use of cell lines in biomedical research.
Br J Cancer. 2014;111(6):1021–46.
38. Dickson MA, et al. Human keratinocytes that express hTERT and also bypass
a p16(INK4a)-enforced mechanism that limits life span become immortal
yet retain normal growth and differentiation characteristics. Mol Cell Biol.
2000;20(4):1436–47.
39. Kiyono T, et al. Both Rb/p16INK4a inactivation and telomerase
activity are required to immortalize human epithelial cells. Nature.
1998;396(6706):84–8.
40. Dimri GP, et al. A biomarker that identifies senescent human cells in culture
and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363–7.
41. AbouHaidar MG, Ivanov IG. Non-enzymatic RNA hydrolysis promoted by the
combined catalytic activity of buffers and magnesium ions. Z Naturforsch C.
1999;54(7–8):542–8.
42. Chen SJ. RNA folding: conformational statistics, folding kinetics, and ion
electrostatics. Annu Rev Biophys. 2008;37:197–214.
43. Koculi E, et al. Charge density of divalent metal cations determines RNA
stability. J Am Chem Soc. 2007;129(9):2676–82.
44. Draper DE. RNA folding: thermodynamic and molecular descriptions of the
roles of ions. Biophys J. 2008;95(12):5489–95.
45. Hertweck M, Mueller MW. Mapping divalent metal ion binding sites in a
group II intron by Mn(2+)- and Zn(2+)-induced site-specific RNA cleavage.
Eur J Biochem. 2001;268(17):4610–20.
46. Xi Y, et al. Systematic analysis of microRNA expression of RNA extracted
from fresh frozen and formalin-fixed paraffin-embedded samples. RNA.
2007;13(10):1668–74.
47. Meng W, et al. Comparison of microRNA deep sequencing of matched
formalin-fixed paraffin-embedded and fresh frozen cancer tissues. PLoS One.
2013;8(5):e64393.
48. Jung M, et al. Robust microRNA stability in degraded RNA preparations
from human tissue and cell samples. Clin Chem. 2010;56(6):998–1006.
49. Peskoe SB, et al. Differential long-term stability of microRNAs and RNU6B
snRNA in 12-20 year old archived formalin-fixed paraffin-embedded
specimens. BMC Cancer. 2017;17(1):32.
50. Rentoft M, et al. miRNA analysis of formalin-fixed squamous cell carcinomas of
the tongue is affected by age of the samples. Int J Oncol. 2011;38(1):61–9.
51. Mall C, et al. Stability of miRNA in human urine supports its biomarker
potential. Biomark Med. 2013;7(4):623–31.
52. Esser C, et al. Isolation of full-size mRNA from ethanol-fixed cells after
cellular immunofluorescence staining and fluorescence-activated cell sorting
(FACS). Cytometry. 1995;21(4):382–6.
53. Evangelou K, et al. Robust, universal biomarker assay to detect senescent
cells in biological specimens. Aging Cell. 2017;16(1):192–7.
54. Georgakopoulou EA, et al. Specific lipofuscin staining as a novel biomarker
to detect replicative and stress-induced senescence. A method applicable in
cryo-preserved and archival tissues. Aging (Albany NY). 2013;5(1):37–50.
55. Gorgoulis VG, et al. Activation of the DNA damage checkpoint and genomic
instability in human precancerous lesions. Nature. 2005;434(7035):907–13.
56. Georgakilas AG, et al. Are common fragile sites merely structural domains or
highly organized “functional” units susceptible to oncogenic stress? Cell Mol
Life Sci. 2014;71(23):4519–44.
57. Ramirez RD, et al. Immortalization of human bronchial epithelial cells in the
absence of viral oncoproteins. Cancer Res. 2004;64(24):9027–34.
58. Evangelou K, et al. The DNA damage checkpoint precedes activation of ARF
in response to escalating oncogenic stress during tumorigenesis. Cell Death
Differ. 2013;20(11):1485–97.
59. Velimezi G, et al. Functional interplay between the DNA-damage-response
kinase ATM and ARF tumour suppressor protein in human cancer. Nat Cell
Biol. 2013;15(8):967–77.
60. Liontos M, et al. Deregulated overexpression of hCdt1 and hCdc6 promotes
malignant behavior. Cancer Res. 2007;67(22):10899–909.
61. Karakaidos P, et al. Overexpression of the replication licensing regulators
hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas:
synergistic effect with mutant p53 on tumor growth and chromosomal
instability–evidence of E2F-1 transcriptional control over hCdt1.
Am J Pathol. 2004;165(4):1351–65.
62. Petrakis TG, et al. Exploring and exploiting the systemic effects of
deregulated replication licensing. Semin Cancer Biol. 2016;37-38:3–15.
63. Sideridou M, et al. Cdc6 expression represses E-cadherin transcription and
activates adjacent replication origins. J Cell Biol. 2011;195(7):1123–40.
64. Galanos P, et al. Chronic p53-independent p21 expression causes genomic
instability by deregulating replication licensing. Nat Cell Biol. 2016;18(7):777–89.
65. Petrakis TG, Vougas K, Gorgoulis VG. Cdc6: a multi-functional molecular
switch with critical role in carcinogenesis. Transcription. 2012;3(3):124–9.
66. Huang S, et al. DNA replication initiator Cdc6 also regulates ribosomal DNA
transcription initiation. J Cell Sci. 2016;129(7):1429–40.
67. Georgakopoulou E, et al. Apoptosis or senescence? Which exit route do
epithelial cells and fibroblasts preferentially follow? Mech Ageing Dev.
2016;156:17–24.
68. Niimi S, et al. Cdc6 protein obstructs apoptosome assembly and
consequent cell death by forming stable complexes with activated Apaf-1
molecules. J Biol Chem. 2012;287(22):18573–83.
69. Narita M, et al. Rb-mediated heterochromatin formation and silencing of
E2F target genes during cellular senescence. Cell. 2003;113(6):703–16.
70. Nieto MA, et al. Emt: 2016. Cell. 2016;166(1):21–45.
71. Thiery JP, et al. Epithelial-mesenchymal transitions in development and
disease. Cell. 2009;139(5):871–90.
72. Liontos M, et al. Modulation of the E2F1-driven cancer cell fate by the DNA
damage response machinery and potential novel E2F1 targets in
osteosarcomas. Am J Pathol. 2009;175(1):376–91.
73. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability–an evolving
hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220–8.
74. d'Adda di Fagagna F. Living on a break: cellular senescence as a
DNA-damage response. Nat Rev Cancer. 2008;8(7):512–22.
75. Walter D, et al. SCF(Cyclin F)-dependent degradation of CDC6 suppresses
DNA re-replication. Nat Commun. 2016;7:10530.
76. Heng HH, et al. Chromosomal instability (CIN): what it is and why it is
crucial to cancer evolution. Cancer Metastasis Rev. 2013;32(3–4):325–40.
77. Rangel N, Forero-Castro M, Rondon-Lagos M. New insights in the
cytogenetic practice: Karyotypic chaos, non-Clonal chromosomal alterations
and chromosomal instability in human cancer and therapy response. Genes
(Basel). 2017;8(6):155.
78. Mrasek K, et al. Global screening and extended nomenclature for 230
aphidicolin-inducible fragile sites, including 61 yet unreported ones.
Int J Oncol. 2010;36(4):929–40.
79. Tan DS, et al. Intertumor heterogeneity of non-small-cell lung carcinomas
revealed by multiplexed mutation profiling and integrative genomics.
Int J Cancer. 2014;135(5):1092–100.
80. Kang J. Genomic alterations on 8p21-p23 are the most frequent genetic
events in stage I squamous cell carcinoma of the lung. Exp Ther Med.
2015;9(2):345–50.
81. Jimenez-Sousa MA, et al. Myelodysplastic syndrome with isochromosome
5p and trisomy 8 after treatment of a multiple myeloma. Cancer Genet
Cytogenet. 2010;203(2):345–7.
82. Hoglund M, et al. Statistical dissection of cytogenetic patterns in lung
cancer reveals multiple modes of karyotypic evolution independent of
histological classification. Cancer Genet Cytogenet. 2004;154(2):99–109.
83. Skourti-Stathaki K, Proudfoot NJ. A double-edged sword: R loops as threats
to genome integrity and powerful regulators of gene expression. Genes
Dev. 2014;28(13):1384–96.
84. Roy D, Lieber MR. G clustering is important for the initiation of
transcription-induced R-loops in vitro, whereas high G density without
clustering is sufficient thereafter. Mol Cell Biol. 2009;29(11):3124–33.
85. Roy D, et al. Competition between the RNA transcript and the nontemplate
DNA strand during R-loop formation in vitro: a nick can serve as a strong
R-loop initiation site. Mol Cell Biol. 2010;30(1):146–59.
86. Xu B, Clayton DA. RNA-DNA hybrid formation at the human mitochondrial
heavy-strand origin ceases at replication start sites: an implication for
RNA-DNA hybrids serving as primers. EMBO J. 1996;15(12):3135–43.
87. Baker TA, Kornberg A. Transcriptional activation of initiation of replication
from the E. Coli chromosomal origin: an RNA-DNA hybrid near oriC. Cell.
1988;55(1):113–23.
88. Carles-Kinch K, Kreuzer KN. RNA-DNA hybrid formation at a bacteriophage
T4 replication origin. J Mol Biol. 1997;266(5):915–26.
Komseli et al. BMC Genomics  (2018) 19:37 Page 21 of 22
89. Masukata H, Tomizawa J. Effects of point mutations on formation
and structure of the RNA primer for ColE1 DNA replication. Cell.
1984;36(2):513–22.
90. Masukata H, Tomizawa J. A mechanism of formation of a persistent hybrid
between elongating RNA and template DNA. Cell. 1990;62(2):331–8.
91. Chan YA, et al. Genome-wide profiling of yeast DNA:RNA hybrid prone sites
with DRIP-chip. PLoS Genet. 2014;10(4):e1004288.
92. El Hage A, et al. Genome-wide distribution of RNA-DNA hybrids identifies
RNase H targets in tRNA genes, retrotransposons and mitochondria.
PLoS Genet. 2014;10(10):e1004716.
93. Starokadomskyy P, et al. DNA polymerase-alpha regulates the activation of
type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol.
2016;17(5):495–504.
94. Lima WF, et al. Viable RNaseH1 knockout mice show RNaseH1 is essential
for R loop processing, mitochondrial and liver function. Nucleic Acids Res.
2016;44(11):5299–312.
95. Chiolo I, et al. Double-strand breaks in heterochromatin move outside
of a dynamic HP1a domain to complete recombinational repair. Cell.
2011;144(5):732–44.
96. van Sluis M, McStay B. A localized nucleolar DNA damage response
facilitates recruitment of the homology-directed repair machinery
independent of cell cycle stage. Genes Dev. 2015;29(11):1151–63.
97. Grob A, Colleran C, McStay B. Construction of synthetic nucleoli in human
cells reveals how a major functional nuclear domain is formed and
propagated through cell division. Genes Dev. 2014;28(3):220–30.
98. Santos-Pereira JM, Aguilera A. R loops: new modulators of genome
dynamics and function. Nat Rev Genet. 2015;16(10):583–97.
99. Boque-Sastre R, et al. Head-to-head antisense transcription and R-loop
formation promotes transcriptional activation. Proc Natl Acad Sci U S A.
2015;112(18):5785–90.
100. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
101. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress
phenotype of cancer cells. Cell. 2007;130(6):986–8.
102. Zaravinos A. The regulatory role of MicroRNAs in EMT and cancer. J Oncol.
2015;2015:865816.
103. Siemens H, et al. miR-34 and SNAIL form a double-negative feedback loop to
regulate epithelial-mesenchymal transitions. Cell Cycle. 2011;10(24):4256–71.
104. He L, et al. microRNAs join the p53 network–another piece in the
tumour-suppression puzzle. Nat Rev Cancer. 2007;7(11):819–22.
105. Disayabutr S, et al. miR-34 miRNAs regulate cellular senescence in type II
alveolar epithelial cells of patients with idiopathic pulmonary fibrosis.
PLoS One. 2016;11(6):e0158367.
106. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or
adaptation. Curr Opin Cell Biol. 2007;19(2):238–45.
107. Rappold I, et al. Tumor suppressor p53 binding protein 1 (53BP1) is involved
in DNA damage-signaling pathways. J Cell Biol. 2001;153(3):613–20.
108. Bartkova J, et al. DNA damage response as a candidate anti-cancer barrier in
early human tumorigenesis. Nature. 2005;434(7035):864–70.
109. Obernosterer G, Martinez J, Alenius M. Locked nucleic acid-based in situ
detection of microRNAs in mouse tissue sections. Nat Protoc. 2007;2(6):1508–14.
110. Sempere LF, Korc M. A method for conducting highly sensitive microRNA in
situ hybridization and immunohistochemical analysis in pancreatic cancer.
Methods Mol Biol. 2013;980:43–59.
111. Nielsen BS, Holmstrom K. Combined microRNA in situ hybridization and
immunohistochemical detection of protein markers. Methods Mol Biol.
2013;986:353–65.
112. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of
complementary RNA and DNA. Biochemistry. 2004;43(42):13233–41.
113. Silahtaroglu AN, et al. Detection of microRNAs in frozen tissue sections by
fluorescence in situ hybridization using locked nucleic acid probes and
tyramide signal amplification. Nat Protoc. 2007;2(10):2520–8.
114. de Planell-Saguer M, Rodicio MC, Mourelatos Z. Rapid in situ codetection of
noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded
tissue sections without protease treatment. Nat Protoc. 2010;5(6):1061–73.
115. Kwon S. Single-molecule fluorescence in situ hybridization: quantitative
imaging of single RNA molecules. BMB Rep. 2013;46(2):65–72.
116. Pena JT, et al. miRNA in situ hybridization in formaldehyde and EDC-fixed
tissues. Nat Methods. 2009;6(2):139–41.
117. Le Magnen C, Dutta A, Abate-Shen C. Optimizing mouse models for
precision cancer prevention. Nat Rev Cancer. 2016;16(3):187–96.
118. Rangarajan A, et al. Species- and cell type-specific requirements for cellular
transformation. Cancer Cell. 2004;6(2):171–83.
119. Kamijo T, et al. Loss of the ARF tumor suppressor reverses premature
replicative arrest but not radiation hypersensitivity arising from disabled atm
function. Cancer Res. 1999;59(10):2464–9.
120. Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by
the alternative reading frame product p19ARF. Cell. 1997;91(5):649–59.
121. Efeyan A, et al. Limited role of murine ATM in oncogene-induced
senescence and p53-dependent tumor suppression. PLoS One.
2009;4(5):e5475.
122. Balmain A, Harris CC. Carcinogenesis in mouse and human cells: parallels
and paradoxes. Carcinogenesis. 2000;21(3):371–7.
123. McStay B, Grummt I. The epigenetics of rRNA genes: from molecular to
chromosome biology. Annu Rev Cell Dev Biol. 2008;24:131–57.
124. Murray JM, Stiff T, Jeggo PA. DNA double-strand break repair within
heterochromatic regions. Biochem Soc Trans. 2012;40(1):173–8.
125. Nakane PK. Simultaneous localization of multiple tissue antigens using the
peroxidase-labeled antibody method: a study on pituitary glands of the rat.
J Histochem Cytochem. 1968;16(9):557–60.
126. Abbadie C, Pluquet O, Pourtier A. Epithelial cell senescence: an adaptive
response to pre-carcinogenic stresses? Cell Mol Life Sci. 2017;74(24):4471–509.
127. Debacq-Chainiaux F, et al. Protocols to detect senescence-associated
beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in
culture and in vivo. Nat Protoc. 2009;4(12):1798–806.
128. Kim D, et al. TopHat2: accurate alignment of transcriptomes in the presence
of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
129. Li H, et al. The sequence alignment/map format and SAMtools.
Bioinformatics. 2009;25(16):2078–9.
130. Anders S, Pyl PT, Huber W. HTSeq–a python framework to work with
high-throughput sequencing data. Bioinformatics. 2015;31(2):166–9.
131. Anders S, Huber W. Differential expression analysis for sequence count data.
Genome Biol. 2010;11(10):R106.
132. Chen S, et al. AfterQC: automatic filtering, trimming, error removing and
quality control for fastq data. BMC Bioinformatics. 2017;18(Suppl 3):80.
133. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat Protoc.
2009;4(1):44–57.
134. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc Natl Acad
Sci U S A. 2005;102(43):15545–50.
135. Backes C, et al. miEAA: microRNA enrichment analysis and annotation.
Nucleic Acids Res. 2016;44(W1):W110–6.
136. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human
microRNAs. Nat Struct Mol Biol. 2006;13(12):1097–101.
137. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol.
2014;15(8):509–24.
138. Winter J, et al. Many roads to maturity: microRNA biogenesis pathways and
their regulation. Nat Cell Biol. 2009;11(3):228–34.
139. Roberts TC. The MicroRNA biology of the mammalian nucleus. Mol Ther
Nucleic Acids. 2014;3:e188.
140. Baradan R, Hollander JM, Das S. Mitochondrial miRNAs in diabetes: just the
tip of the iceberg. Can J Physiol Pharmacol. 2017;95:1156–62.
141. Makarova JA, et al. Intracellular and extracellular microRNA: an update on
localization and biological role. Prog Histochem Cytochem. 2016;51(3–4):33–49.
142. Treiber T, et al. A compendium of RNA-binding proteins that regulate
MicroRNA biogenesis. Mol Cell. 2017;66(2):270–84. e13
143. Sakellariou D, et al. Alternative lengthening of telomeres: recurrent
cytogenetic aberrations and chromosome stability under extreme telomere
dysfunction. Neoplasia. 2013;15(11):1301–13.
Komseli et al. BMC Genomics  (2018) 19:37 Page 22 of 22
